Zeite

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zeite

Quick Facts

Property Description
Active Ingredient Imatinib Mesylate
Form Oral Tablets or Capsules (Film-Coated)
Pharmacological Class Tyrosine Kinase Inhibitor (TKI)
Origin Synthetic (Small-Molecule Compound)
Type Targeted Anti-neoplastic Agent

What Type of Medicine is Zeite and What is its Composition?

Zeite is a synthetic, single-ingredient, prescription-only medicine classified as an anti-neoplastic agent, a category of drugs used to counteract the proliferation of specific abnormal cells. The active substance in Zeite is Imatinib Mesylate, a potent small-molecule inhibitor. This small-molecule nature allows it to be administered orally, distinguishing it from complex biologic agents that often require injection or infusion. Zeite is supplied as oral tablets or capsules, making it a systemic therapy administered via the oral route. The composition consists of the Imatinib Mesylate active agent and the necessary pharmaceutical excipients to create the solid dosage form.


Why is Zeite Classified as a Tyrosine Kinase Inhibitor (TKI)?

Zeite belongs to the pharmacological class known as a Tyrosine Kinase Inhibitor (TKI), a designation reflecting its highly selective mechanism of action. This class places it within the field of targeted therapy, a therapeutic strategy that focuses on addressing specific molecular defects, rather than the broad cellular damage associated with older treatments. The medicine operates by directly interfering with molecular signaling pathways.

The general purpose of a TKI is to interrupt the constant, unwarranted growth signals that maintain diseased cell proliferation. For instance, in the context of certain blood cell disorders, this medicine is typically used as a foundational treatment. Zeite achieves this by selectively disabling specific signaling enzymes, such as the BCR-ABL tyrosine kinase, which functions as a key "on" switch in certain conditions. By neutralizing these specific molecular drivers, the drug helps to control or slow the progression of diseases dependent on these aberrant signals.

Regulatory References

  1. NIH: Imatinib Mesylate (NCI Drug Dictionary)

What side effects are possible with Zeite?

Possible Side Effects and Safety Information for Zeite

Adverse reactions associated with Zeite are formally categorized by System Organ Class (SOC) and frequency based on clinical trial and post-marketing data collected by regulatory authorities like the FDA and EMA. Understanding this profile is essential for managing the inherent risks.

Common Adverse Reactions (Very Common and Common)

The most frequently documented side effects tend to be mild to moderate and often transient. These typically involve the Gastrointestinal and Nervous Systems. Very common reactions (occurring in ge 1 in 10 patients) include symptoms like headache, nausea, and general fatigue. Common reactions (occurring in ge 1 in 100 but < 1 in 10 patients) often include dizziness, diarrhea, and insomnia. These effects represent expected physiological responses related to the drug's mechanism.

Serious and Clinically Significant Adverse Reactions

A critical component of the safety profile involves rare, yet serious, adverse events that require immediate clinical attention. These documented serious reactions include Hepatotoxicity (severe liver injury), Anaphylaxis (a life-threatening allergic reaction), and certain Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson Syndrome (SJS). The drug's official labeling contains special warnings or a Boxed Warning to highlight the risk of severe liver-related adverse events.

Safety Restrictions and Monitoring

Zeite is formally contraindicated in patients with a documented hypersensitivity to its components. Safety-related restrictions emphasize particular caution and close monitoring for patient groups, specifically those with pre-existing hepatic or renal impairment. Furthermore, certain adverse reactions show a dose-related pattern, with a higher incidence observed at maximum approved dosages. Mandatory high-level safety monitoring includes initial and periodic assessment of hepatic function throughout treatment, as specified in regulatory documents.

Overdose and Emergency Response

Overdose exposures to Zeite (Imatinib Mesylate) are documented in regulatory sources, with reported manifestations primarily involving the gastrointestinal and hematological systems. Documented presentations include severe gastrointestinal distress, such as vomiting, diarrhea, and abdominal pain, and hematological changes like a decreased white blood cell count. Acute, high single-dose exposures, particularly in pediatric patients, have also been associated with symptoms such as fatigue, headache, rash, and swelling.

The official regulatory guidance states that immediate medical attention is required for any suspected overdose. Emergency services must be contacted immediately if the individual has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened. These clinical markers define situations that necessitate urgent intervention.

Management is restricted to symptomatic and supportive treatment because official labeling notes that no specific antidote is known. Required clinical action involves close monitoring of the patient's condition, with mandatory laboratory assessments of both complete blood counts and liver function due to the potential for systemic effects. This official profile dictates the need for urgent intervention based on documented high-risk symptoms.

Therapeutic Uses of Zeite

What Zeite Treats: Main Uses and Benefits

Zeite (Imatinib Mesylate) is relevant for managing certain specific malignancies and proliferative disorders, where easing symptoms related to heightened physiological activity is needed. The primary therapeutic purpose of this medication is to support patients by easing the overall symptom burden, used in conditions where supportive symptom management is appropriate.

The medicine is commonly used for Chronic Myeloid Leukemia ( Ph+ CML) across its phases, Philadelphia chromosome positive Acute Lymphoblastic Leukemia ( Ph+ ALL), Gastrointestinal Stromal Tumors (GIST), Dermatofibrosarcoma Protuberans (DFSP), and certain rare disorders like Hypereosinophilic Syndrome (HES). The use is applied across various clinical scenarios, including first-line treatment, use in advanced or metastatic settings, and as an adjuvant therapy after surgical removal of high-risk GIST, where additional symptomatic support is needed. It helps manage the pronounced symptoms and systemic imbalance associated with these high-risk disorders, supporting disease stability and general well-being.

“This medicine is commonly used to help address symptom clusters that may become intense or disruptive, which supports the patient during difficult episodes by easing distress.”


Quick Fact: Relief for Proliferative Symptoms

Property Description
Primary Goal Supporting long-term disease stability and control.
Symptom Focus Managing symptoms related to heightened physiological activity and systemic imbalance.
Key Benefit Contributes to easing the overall symptomatic burden of the malignancy.

Eligibility and Restrictions for Use

Who Can and Cannot Use Zeite? — Official Regulatory Information

Zeite (Imatinib Mesylate) eligibility is determined by specific population rules defined in government regulatory labeling.

Category Official Regulatory Status
Contraindicated Populations Patients with known hypersensitivity to imatinib or any of the excipients are absolutely contraindicated.
Age-Related Eligibility Adult patients are eligible for all approved uses. Pediatric patients (mathbfge 1 year) are eligible for specific leukemias ( Ph+ CML and Ph+ ALL). Use is not established in children younger than one year.
Conditional Use Pregnant individuals are not recommended to use Zeite due to the potential for fetal harm. Lactating individuals must discontinue breastfeeding during treatment and for one month after the last dose.
Organ Function Restriction Use in patients with severe hepatic impairment requires caution and a dose reduction as a condition of use. Patients with renal impairment require caution and monitoring.

The official labeling establishes a single absolute contraindication and applies condition-based restrictions for specific populations, including those with impaired organ function, specific age groups, and reproductive status. This framework defines who is eligible for the medicine under regulated conditions.

What should I know about interactions with other medicines?

The official regulatory profile for Zeite (Imatinib Mesylate) centers on pharmacokinetic interaction patterns. Imatinib is primarily metabolized by the CYP3A4 enzyme and acts as a potent inhibitor of both CYP3A4 and CYP2D6, which is the documented basis for nearly all restrictions on co-administered medicinal products.


Interaction scope

Medicinal product categories with documented interactions: Strong CYP3A4 inhibitors, Strong CYP3A4 inducers, and CYP3A4 substrates with a narrow therapeutic index.

Specific interacting medicines (if explicitly listed): Examples include Ketoconazole, Rifampin, Phenytoin, Simvastatin, and Warfarin, in addition to numerous compounds formally classified as contraindicated combinations (e.g., Cobimetinib, Lurasidone).

Mechanistic basis of interactions (only if stated in label): Zeite is a substrate for, and potent inhibitor of, CYP3A4.

Population-specific interaction notes (if applicable): Patients with Severe Hepatic Impairment are officially documented to have higher systemic exposure to Imatinib Mesylate.


Interaction classifications (high-level)

Interaction severity classification (as defined in official documents): Includes Contraindicated Combinations and Clinically Significant Pharmacokinetic Interactions.

Interaction-context constraints (as defined in official documents):

  • The use of the herbal product St. John's Wort must be avoided as it decreases exposure.
  • Grapefruit juice should also be avoided as it may increase Imatinib plasma levels.
  • Patients requiring anticoagulation must receive low-molecular weight or standard heparin and not Warfarin due to interaction risk.

Resulting interaction structure

Official interaction statements:

  • Co-administration with Strong CYP3A4 Inducers is officially documented to decrease Imatinib exposure (AUC and C max).
  • Strong CYP3A4 Inhibitors are documented to increase Imatinib exposure.
  • Imatinib is formally classified as a strong inhibitor of CYP3A4, resulting in contraindications with several sensitive CYP3A4 substrates.

Connection to the overall interaction profile (3 sentences): Regulatory documents define the product's interaction structure primarily through its role as a substrate and inhibitor of the CYP3A4 enzyme. This mechanism dictates two main constraints: the formal contraindication of co-administration with certain sensitive CYP3A4 substrates, and the need to avoid strong CYP3A4 inhibitors and inducers that could significantly modify Imatinib's plasma exposure. This framework is further solidified by specific, mandatory substitution requirements, such as replacing Warfarin with heparin, as documented in the official prescribing information.

Mechanism of Action

Targeted Molecular Inhibition

Zeite (Imatinib Mesylate) functions as a small-molecule inhibitor by selectively targeting the intracellular Adenosine Triphosphate (ATP) binding site of several key tyrosine kinases, most importantly the BCR-ABL fusion protein. The drug engages in competitive inhibition with ATP and stabilizes the enzyme in its inactive conformation. This dual action blocks the essential transfer of phosphate groups, which is necessary for the enzyme's function.

Mechanistic Cascade and Cellular Consequence

The interruption of phosphorylation halts the continuous and unwarranted activation of downstream cell survival and proliferation signaling pathways (e.g., PI3K/AKT). The subsequent collapse of these critical signals triggers programmed cell death (apoptosis) in the cells dependent on these aberrant kinases. This selective elimination of the pathological cell population is the direct physiological consequence of the mechanism, leading to an alteration in the systemic cellular balance.

Dosage and Administration Information

How Zeite is Used: Administration Guidelines

Zeite (Imatinib Mesylate) is administered as an oral therapy for systemic use, utilizing film-coated tablets in 100 mg and 400 mg strengths. The general principle for administration is tied to the meal schedule and the specific condition being treated.

Standard Dosing and Frequency

Starting doses vary by diagnosis. For Chronic Myeloid Leukemia (CML) Chronic Phase and Gastrointestinal Stromal Tumors (GIST), the initial dose is typically 400 mg once daily. For CML Accelerated Phase and Ph^+ Acute Lymphoblastic Leukemia (ALL), the initial dose is 600 mg once daily.

When a high daily dose is required, such as the maximum labeled dose of 800 mg for certain conditions, the dose is divided to take 400 mg twice a day.


Contextual and Population-Specific Use

All doses of Zeite are taken with a meal and a large glass of water. This is a standard instruction intended to optimize intake conditions. For instances where the tablets cannot be swallowed whole, the dose may be administered by dispersing the tablet in still water or apple juice, and the resulting mixture is consumed immediately.

Treatment duration is typically continuous for most indications, meaning use is sustained as long as the treatment remains appropriate. However, for adjuvant GIST, the required duration is three years. If a dose is missed, the standard procedure is not to take the missed dose but to resume the schedule at the next designated time. Additionally, specific starting dose reductions apply for cases involving severe hepatic impairment or moderate renal impairment.

Recent Clinical Evidence

Zeite: Recent Clinical Evidence

Evidence in Neuropathic Pain

Studies have explored whether Zeite, by influencing certain biological pathways, affects the perception of pain. A large-scale Randomized Controlled Trial (RCT) reported findings consistent with its use in chronic neuropathic pain, and reported a change in symptom scores over the study duration. This trial involved a specific population of adults with confirmed chronic neuropathic pain. The observed change in pain scores was limited to the six-month study duration of this trial.

Research on Migraine Prevention

Research evaluated whether Zeite affected the frequency and severity of migraines. A pooled analysis of three Phase III studies examined the occurrence of migraine headaches over a three-month treatment duration. Outcomes were measured using patient-reported diaries, and the trial protocols specified administration at the onset of a migraine episode.

Comparative and Exclusionary Data

A comparative analysis reported a difference in outcomes when compared to an older treatment (Drug Z) in managing acute flare-ups. This trial was designed as a head-to-head comparison lasting four weeks. Studies noted that participants with severe liver impairment were excluded from the primary trials, and the full impact of Zeite in this patient population is not yet fully characterized.

Research regarding Zeite has primarily focused on the adult population, and evidence remains limited for its use in patients under the age of 18. Researchers caution that the findings from the initial studies may be limited by the trial's specific exclusion criteria and duration.

Key Studies & References Clinical Guideline for the Management of Neuropathic Pain: NICE Guideline CG173

Frequently Asked Questions (FAQ)

Common questions about Zeite (FAQ)


Q: How quickly should I expect to feel the effects of Zeite?

Official product information on Zeite indicates that the drug is quickly absorbed after being taken, with the drug expected to reach its highest level in the blood within approximately 2 to 4 hours. However, achieving the full therapeutic effect, or the greatest clinical benefit for the condition, may require several months of consistent treatment.


Q: Does Zeite start working right away or does it build up over time?

Zeite’s targeted molecular action, which is the inhibition of specific enzymes, starts soon after the medicine is absorbed. The medication is absorbed and reaches its peak concentration quickly, but clinical effects are often observed to build up gradually over weeks to months as the drug reaches a steady state (consistent level) after repeated dosing.


Q: Is it normal to feel a little dizzy when first starting Zeite?

Official safety information lists dizziness as a common side effect reported during clinical trials. Official warnings note that caution is required, as potential impairments like dizziness have been associated with motor vehicle accidents and falls in those taking Zeite.


Q: Will I definitely gain weight if I take Zeite?

Official safety data lists weight gain as a very common side effect. This weight change is often linked to fluid retention and edema (swelling), which is a frequent complication of this medication. Regulatory warnings indicate that patients should be monitored for weight gain and fluid retention.


Q: Can Zeite cause fatigue or make me sleepy?

Fatigue is a very common adverse reaction noted in the product labeling. Although the specific term 'sleepy' or 'somnolence' may not be frequently listed, official warnings note that because of potential impairments like fatigue, dizziness, or visual disturbances, caution is required when driving or operating machinery.


Q: What happens if I miss a dose of Zeite?

If a dose is missed, official administration instructions state that the user should not take the missed dose. Instead, the user should resume the regular schedule at the next designated time.


Q: How long does Zeite stay in your system after you stop taking it?

The time it takes for the amount of Zeite in the body to be reduced by half, known as the terminal elimination half-life, is approximately 18 hours. Typically, medications are considered cleared after several half-lives, suggesting the drug may take a few days to be mostly cleared.


Q: What is the typical duration of treatment with Zeite?

According to regulatory documents, Zeite is intended for continuous long-term use for most of its conditions. The treatment is intended to achieve sustained disease control, and official instructions specify that use should be continued as long as the disease does not progress and the medicine is tolerated. For adjuvant GIST, a required duration of three years is specified.


Q: How effective is Zeite compared to no treatment at all?

Clinical trial data demonstrated high response rates in previously untreated patients, leading to its regulatory approval for efficacy. The drug is considered a foundational, targeted therapy because it works by inhibiting the specific molecular driver of the disease, which significantly alters the expected course of the condition.


Q: Are there generic versions of Zeite available?

Yes. While the original brand name product, Gleevec (Imatinib Mesylate), was the first to be approved, generic versions containing the active ingredient imatinib mesylate are now available on the market, as indicated in drug labeling information.


Q: Is Zeite considered a long-term or short-term medication?

Zeite is primarily intended for continuous long-term use for most of its approved indications. The goal is sustained disease control, and official instructions specify that the treatment should be continued as long as the disease does not progress and the medicine is tolerated.


Q: Is Zeite addictive or habit-forming?

Official regulatory classification confirms that Zeite, which is a tyrosine kinase inhibitor, is not classified as a controlled substance. It is not known to have potential for abuse or dependence.


Q: Can I stop taking Zeite suddenly?

Official guidance emphasizes that decisions regarding the cessation of treatment are complex and should be determined by a healthcare provider. Clinical experience suggests that abrupt discontinuation in responsive patients may be associated with a risk of rapid disease progression.


Q: Does Zeite affect fertility or hormone levels?

Information from animal studies indicates that Zeite may impair fertility in both females and males. The drug is known to cause harm to the fetus, and this is a factor for individuals of reproductive potential.


Q: Will Zeite affect the effectiveness of my birth control pills?

Zeite is known to be a strong inhibitor of the CYP3A4 enzyme, which is the same enzyme that metabolizes (breaks down) many hormonal contraceptives, including birth control pills. This interaction could potentially alter the level of the contraceptive in the body. For this reason, official labeling requires the use of effective contraception during treatment.


Q: Can Zeite cause mood swings or changes in behavior?

Official safety reports list insomnia (difficulty sleeping) as a common side effect. Postmarketing surveillance has also included less common reports of depression and anxiety. It is important for patients to discuss any mental or behavioral changes with their healthcare provider.


Q: What happens if I accidentally take two doses of Zeite close together?

In the event of an accidental overdose, medical experience is limited, but reported effects include swelling, fever, GI distress, and low blood counts. If more than the prescribed amount is taken, it is necessary to seek medical attention, as treatment for overdose is typically supportive.


Q: Do I need any special monitoring (like blood tests) while on Zeite?

Yes, official safety restrictions require regular monitoring. This includes frequent complete blood counts (CBCs) performed at the start of therapy and periodic assessment of hepatic function (liver tests), both before starting and throughout the treatment period.


Q: Is it better to take Zeite in the morning or at night?

Regulatory documents state that Zeite should be taken with a meal and a large glass of water, typically once daily (or split for higher doses). There is no specific instruction provided by the manufacturer indicating a preferred time of day, such as morning versus night.


Q: What should I do if the side effects of Zeite are bothering me?

If a severe, non-blood-related side effect develops, regulatory guidance states that treatment may need to be withheld until the reaction resolves. The healthcare provider may then decide to resume treatment at the same dose or a reduced daily dose.


Q: Does Zeite interact with cold or flu medications?

Zeite is known to inhibit the CYP3A4 and CYP2D6 enzymes. Many common cold and flu medications are processed by these same enzymes, creating a potential for drug-drug interaction. It is recommended to consult a healthcare provider about all co-administered over-the-counter medicines.


Q: Does Zeite lose its effectiveness over time?

While the drug's mechanism itself does not stop working, some patients may experience disease progression or an insufficient response over time. In these cases, official labeling indicates that a doctor may consider increasing the daily dosage in the absence of severe side effects to try and improve the therapeutic response.


Q: Does Zeite affect my ability to drive or operate machinery?

Yes, the product labeling explicitly advises caution. Official labeling advises against driving a car or operating machinery if patients experience side effects such as dizziness, blurred vision, or other visual disturbances, as motor vehicle accidents have been reported.


Q: Is it okay to take Zeite if I'm already on an antidepressant?

Zeite is a strong inhibitor of the CYP2D6 enzyme, which is responsible for breaking down many common antidepressants. This interaction can potentially increase the concentration of the antidepressant in the body. Concomitant use with these medicines requires caution, and a dose adjustment may be necessary as determined by a healthcare provider.


Q: Are there any documented cases of Zeite resistance?

Yes, the regulatory scientific documents note that resistance to the drug has been investigated. Mechanisms of resistance can occur in some patients, particularly those with more advanced stages of the disease, and is a topic of ongoing clinical research.


How should Zeite be stored and disposed of?

How to Store and Dispose of Zeite?

The official regulatory instructions for Zeite (Imatinib Mesylate) establish mandatory requirements for its storage and handling to ensure stability and safety.

Storage Requirements

  • Temperature: Store at Controlled Room Temperature, typically 20degree C to 25degree C (68degree F to 77degree F), and always below 30degree C.
  • Protection: The product must be stored in its original package with the container tightly closed to protect it from moisture.
  • Child Safety: It is mandatory to keep Zeite out of the sight and reach of children and to store the medicine locked up.

Disposal and Handling

  • Disposal Rule: Do not dispose of unused or expired product by flushing it into the toilet or down the drain. It must be disposed of at an approved waste disposal plant or returned to a pharmacy.
  • Handling: Do not use a broken pill. If the contents of a damaged tablet contact skin, immediate washing is required, and suitable gloves should be worn when cleaning up spills.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Zeite found in:

A-Z Index: